Ondine Biomedical Inc.

Ondine Biomedical Inc. is a Canadian life sciences company specializing in photodisinfection (antimicrobial photodynamic therapy) technologies for infection prevention and treatment. The company's patented platform uses non-thermal laser light activation with photosensitive agents to destroy bacteria, viruses, yeasts, fungi, and associated virulence factors within minutes—without generating antimicrobial resistance. The lead product, Steriwave, is a rapid nasal decolonization therapy that eliminates broad-spectrum pathogens including methicillin-resistant Staphylococcus aureus (MRSA), Candida auris, and SARS-CoV-2 from the nasal cavity, significantly reducing healthcare-associated infections (HAIs) and surgical site infections (SSIs). Clinical evidence from major Canadian hospitals demonstrates up to 84% reduction in postoperative infection rates and 39.5% pneumonia reduction in ICU settings. Photodisinfection offers advantages over traditional antibiotics including immediate pathogen destruction, potent anti-inflammatory effects, and safety for patient outcomes. The company maintains a pipeline of investigational products addressing chronic rhinosinusitis, burn and wound decolonization, endotracheal tube disinfection to prevent ventilator-associated pneumonia, and topical antiviral therapies for upper respiratory tract infections. Ondine's technology platform is designed for straightforward clinical adoption with minimal workflow disruption and no complex compliance barriers. Note: Products are not currently for sale in the United States. The company operates as a specialized biomedical device and therapeutic solutions provider focused on addressing antimicrobial resistance through innovative light-activated infection control mechanisms.